The Company was founded with the mission of developing and commercializing a novel therapeutic vaccine to treat and prevent Type 1 Diabetes Mellitus (T1DM). The Company's drug is result of the many years of research by Dr. Tihamer Orban and his colleagues at the Joslin Diabetes Center aimed at gaining a better understanding of the immulogical mechanisms underlying T1DM. The Company's insulin B chain vaccine for T1DM has successfully completed a Phase I clinical trial and the drug is now poised to enter a Phase II clinical trial to evaluate dosing and metabolic effect. The Company's autoantigen based vaccine targets the root cause of T1DM: the loss of self tolerance and the resultant progressive destruction of insulin-producing beta cells. The loss of self tolerance to insulin, a primary